Christina Mikkelsen

Forum Replies Created

Viewing 6 posts - 1 through 6 (of 6 total)
  • Author
    Posts
  • in reply to: Transpose 4th Newsletter #960

    Christina Mikkelsen
    Participant

    WP5

    In the end of June 2019, the WP5 submitted their D.5.2 report on donor eligibility criteria and the D.5.3 report on guiding principles for donor selection. The first included all the 74 risk assessments performed by the WP5 members. We are now working on completing our three papers, two describing current risks to donors and recipients and one presenting the results of the TRANSPOSE recommendations for donor selection.
    The D.5.4 recommendations for donor selection is currently been reviewed and commented by both the TRANSPOSE Advisory Board as well as Collaboratory Stakeholders. We have also invited experts from other international organizations to comment, as well as members of the EDQM.
    The recommendations will be finalized in August and September, where our members will discuss the comments and suggestions received. The final version will be submitted by the end of September 2019.

    in reply to: Updated Documents June 2019” #906

    Christina Mikkelsen
    Participant

    report

    Attachments:
    You must be logged in to view attached files.
    in reply to: Guidelines wholeblood and plasma v1 #883

    Christina Mikkelsen
    Participant

    also with T&C

    Attachments:
    You must be logged in to view attached files.
    in reply to: Risk assessments for commenting #854

    Christina Mikkelsen
    Participant

    Risk assessment on hemochromatosis

    Attachments:
    You must be logged in to view attached files.
    in reply to: WP5 status April 2019 #795

    Christina Mikkelsen
    Participant

    April 2019

    Attachments:
    You must be logged in to view attached files.
    in reply to: Transpose 3rd Newsletter #782

    Christina Mikkelsen
    Participant

    Dear WP2, thank you for reminding us:) Please find the news from WP5 below.

    WP5 Newsletter April 2019

    Since the meeting in Copenhagen in September 2018, WP5 members have made risk assessments of current donor eligibility criteria as well as proposed new ones, identified as part of the first WP5 deliverables (described in the first newsletter). The results are now being comprised into a scientific paper and a report.
    Based on this work, the first draft of new guiding principles and guidelines for donor selection was commenced in the early spring 2019. The first draft of guidelines for the selection of donors of whole blood was discussed in a workshop in Amsterdam together with represents from WP3, WP5, WP6 and WP7. Subgroups working with plasma and cells and ART will meet in May to finalize their first draft. The results will be discussed in a teleconference at the end of May in order to complete the work on time by the end of June.
    Alongside this work, WP5 have had two abstracts accepted for the 29th regional congress of the International Society for Blood Transfusion (ISBT) in Basel in June 2019 with the titles “A COMPARISON BETWEEN DIRECTIVE 2004/33/EC AND AN EVALUATION BY EXPERTS IN THE TRANSPOSE PROJECT IDENTIFIES INCONGRUENCE IN WHOLE BLOOD DONOR SELECTION CRITERIA” and LARGE DIFFERENCES IN THE REPORTING OF ADVERSE REACTIONS IN BLOOD AND PLASMA DONATION WITHIN THE EUROPEAN UNION – RESULTS FROM THE TRANSPOSE PROJECT.

Viewing 6 posts - 1 through 6 (of 6 total)
Login